Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes: Meta-Analysis

Abstract

DPP-4 inhibitors were associated with a reduction in A1C with comparable safety profiles compared to placebo, but no significant difference in A1C compared to other hyperglycemics. Differences in efficacy and safety were observed between Japanese and non-Japanese patients.

Safety and efficacy of teneligliptin in Japanese patients with type 2 diabetes mellitus: a pooled analysis of two Phase III clinical studies

“…HbA 1c was significantly lower at week 52 than at baseline in all groups. DPP-4 inhibitors have a neutral or positive effect on bodyweight [14,15]. We observed a tendency toward weight gain of 0.3 --0.5 kg with monotherapy or combination therapy with a sulfonylurea or glinide at the end of 52 weeks; these differences, albeit small, were statistically significant at the end of 52 weeks.…”

“…Completed n = 68 Differences in the efficacy of DPP-4 inhibitors have been observed between Asian and non-Asian or Japanese and non-Japanese patients [14,15]. Because of these observed differences between populations, data from Japanese patients are important to evaluate the utility of DPP-4 inhibitors in the Japanese setting.…”

Cardiovascular Effects of Dipeptidyl Peptidase-4 Inhibitors: From Risk Factors to Clinical Outcomes

“…In the 17 active comparator trials, there was no significant difference in A1c reduction (WMD 0.04%; 95% CI -0.09 to 0.16) 42 . No clinically relevant difference in A1c was observed in comparison with thiazolidinediones, α-glucosidase inhibitors or sulfonylureas, whereas metformin produced a slightly greater reduction in A1c 21,[43][44][45] .…”

“…In a recent meta-analysis of 62 evaluated articles concerning trials of at least 12 weeks, DPP-4 inhibitors lowered glycated hemoglobin (A1c) significantly more than placebo (weighted mean difference [WMD] -0.76%; 95% confidence interval or CI -0.83 to -0.68) 42 .…”

Relationship between deterioration of glycated hemoglobin‐lowering effects in dipeptidyl peptidase‐4 inhibitor monotherapy and dietary habits: Retrospective analysis of Japanese individuals with type 2 diabetes

“…Previous studies have shown that DPP4is exert greater glycated hemoglobin (HbA1c)‐lowering effects (HLE) in East Asians3, 4. This enhanced efficacy has been attributed to the unique type 2 diabetes phenotype in East Asians, who tend to be non‐obese and to show β‐cell dysfunction2, 5.…”